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Identification of a bone morphogenetic 
protein type 2 receptor neutralizing antibody
Ruthann E. Gorrell†, Madeline H. Totten†, Laura J. Schoerning, Jordan B. Newby, Logan J. Geyman, 
Warren G. Lawless, Julia M. Hum and Jonathan W. Lowery* 
Abstract 
Objective: The bone morphogenetic protein (BMP) signaling pathway comprises the largest subdivision of the trans-
forming growth factor (TGFβ) superfamily. BMP signaling plays essential roles in both embryonic development and 
postnatal tissue homeostasis. Dysregulated BMP signaling underlies human pathologies ranging from pulmonary arterial 
hypertension to heterotopic ossification. Thus, understanding the basic mechanisms and regulation of BMP signaling 
may yield translational opportunities. Unfortunately, limited tools are available to evaluate this pathway, and genetic 
approaches are frequently confounded by developmental requirements or ability of pathway components to compensate 
for one another. Specific inhibitors for type 2 receptors are poorly represented. Thus, we sought to identify and validate an 
antibody that neutralizes the ligand-binding function of BMP receptor type 2 (BMPR2) extracellular domain (ECD).
Results: Using a modified, cell-free immunoprecipitation assay, we examined the neutralizing ability of the mouse 
monoclonal antibody 3F6 and found a dose-dependent inhibition of BMPR2-ECD ligand-binding. Consistent with this, 
3F6 blocks endogenous BMPR2 function in the BMP-responsive cell line HEK293T. The specificity of 3F6 action was 
confirmed by demonstrating that this antibody has no effect on BMP-responsiveness in HEK293T cells in which BMPR2 
expression is knocked-down. Our results provide important proof-of-concept data for future studies interrogating 
BMPR2 function.
Keywords: Bone morphogenetic protein, Bone morphogenetic protein receptor type 2, Neutralizing antibody, BMP, 
BMPR2, SMAD
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Introduction
The TGF-β superfamily is a group of pleiotropic cytokines 
and their receptors that contribute to metazoan cellular 
development and regulation [1]. Extracellular dimeric 
ligands bind to transmembrane serine/threonine kinase 
receptor complexes, bringing together two type 1 and 
two type 2 receptors, in order to activate a group of effec-
tors called SMAD proteins [1–3]. The largest subdivision 
of this superfamily is comprised of the bone morphoge-
netic proteins (BMPs), which activate SMADs 1, 5, and 8 
and play an essential role in embryonic development and 
in postnatal tissue homeostasis [4]. Moreover, dysregu-
lated BMP signaling underlies numerous human patholo-
gies ranging from pulmonary arterial hypertension to 
heterotopic ossification [5]. Thus, understanding of the 
basic mechanisms by which BMP signaling occurs and is 
regulated is a highly important goal and may yield trans-
lational opportunities.
Functional studies evaluating BMP pathway mechanics, 
such as global or conditional genetic knockout of specific 
components, have been complicated by developmental 
requirements and/or the ability of pathway components 
to compensate for one another [4]. Additionally, the 
translational potential of these strategies is questionable 
due to ethical concerns and technical limitations [5]. This 
has led to the development of several pharmacologically-
based strategies, including decoy receptors and small 
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molecule inhibitors, for non-genetic based modulation 
of BMP pathway activity [6]. That said, the repertoire 
of these molecules remains limited and, in particular, 
few tools exist for inhibiting the function of type 2 BMP 
receptors, the activity of which are essential for initiating 
signal transduction.
In this study, we sought to identify and validate a 
commercially available antibody that neutralizes the 
ligand-binding function of bone morphogenetic protein 
receptor type 2 (BMPR2), which is essential for embry-
ogenesis and has been shown to play clinically-relevant 
roles in pulmonary vascular homeostasis and remodeling 
of the postnatal skeleton [5]. We developed a modified, 
cell-free immunoprecipitation assay quantified by ELISA 
and found that the mouse monoclonal antibody 3F6 
inhibits ligand-binding by BMPR2 in a dose-dependent 
manner. Additionally, using a BMP-responsive cell line 
we found that pre-treatment with 3F6 leads to reduced 
sensitivity in response to BMP pathway activation by 
BMP2. These results provide important proof-of-concept 
data for future studies interrogating BMPR2 function in 
numerous physiological and pathophysiological contexts.
Main text
Materials and methods
Modified immunoprecipitation assay and ELISA
Ligand-binding by BMPR2-ECD was performed as previ-
ously described [7] with the modifications detailed below. 
BMPR2-ECD/Fc fusion (Sino Biologicals 10551-H03H) 
was mixed with 5 µL Protein G-coupled Dynabeads (Inv-
itrogen 1003D) at room temperature for 30 min in 200 µL 
total volume with gentle rocking. The loaded beads were 
then washed twice with PBS and resuspended in 135 μL 
PBS ± 3F6 (Thermo Fisher Scientific Cat# MA5-15827) 
or control ascites (Sigma M8273) and mixed for 1  h at 
room temperature with gentle rocking. 800  ng recom-
binant human BMP2 (R&D Systems 892143) was added 
to the beads and incubated overnight at 4  °C with gen-
tle rocking. The supernatant was removed and examined 
using a Quantikine Human BMP2 Immunoassay ELISA 
(R&D Systems DBP200) according to the manufacturer’s 
instructions.
Cell‑based BMP2‑responsiveness assay
HEK293T cells, obtained from ATCC, were cultured 
in DMEM supplemented with 10% fetal bovine serum 
(FBS) (Gibco), hereafter referred to as “10% DMEM,” 
and grown at 37 °C in 5%  CO2. Cells were not tested for 
mycoplasma contamination. For BMP2-responsiveness 
assays, cells were passaged at 1 million per well in 6-well 
dishes in 10% DMEM on day 0; on day 1 the medium 
was exchanged to DMEM containing 0.5% FBS. After 
approximately 24 h of serum restriction, select wells were 
treated with 250 ng/mL 3F6 or control ascites for 30 min 
followed by 100 ng/mL rhBMP2 for 4 h.
Knockdown of  BMPR2 expression 1.6 × 104 cells in 
100 µL 10% DMEM were added to wells of a 96-well plate. 
The cells were incubated overnight at 37 °C in a humidified 
incubator in an atmosphere of 5%  CO2. After 18–20 h, the 
media was aspirated from the wells. Next, 110 µL of 10% 
DMEM containing 8 μg/mL hexadimethrine bromide was 
added to each well and the plate was gently swirled to 
mix. To each well, lentivirus containing scramble control 
(Sigma SHC002V) or anti-human BMPR2 shRNA (Sigma 
TRCN0000000460) were added and the plate was gently 
swirled to mix. The volume of virus added was calculated 
using a multiplicity of infection of 5. The cells were incu-
bated overnight at 37 °C in a humidified incubator in an 
atmosphere of 5%  CO2. After 18–20  h, the media con-
taining lentiviral particles was removed from the wells. 
A volume of 120 μL of fresh 10% DMEM was added to 
each well, and the plate was returned to the incubator. 
After 18–20  h, the media was removed from the wells, 
and fresh media containing 2  µg/mL puromycin in 10% 
DMEM was added in order to select for the transduced 
cells. The media was replaced with fresh puromycin-
containing media every 3–4 days. When the cells reached 
80% confluence, they were expanded, continuing to be 
maintained in puromycin-containing media. RNA was 
collected from scramble control and BMPR2 knock-down 
(BMPR2-KD) HEK293T cells using the RNEasy Plus Uni-
versal Kit (QIAGEN). cDNA was generated using Super-
Script III First-Strand Synthesis Kit (Thermo Fisher Sci-
entific 18080051). Quantitative RT-PCR was performed 
using TaqMan probes targeting BMPR2 (Thermo Fisher 
Scientific Hs00176148) and HPRT1 (Thermo Fisher Sci-
entific Hs99999909); data were analyzed using the  2−∆∆Ct 
method and normalized to scramble control. Immunblots 
to confirm reduced BMPR2 protein level were described 
as below.
Immunoblots
Immunoblots were performed on protein isolates from 
HEK293T cells after lysis in RIPA buffer (50  mM Tris 
Base, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, pH 8.0) supplemented with Halt Pro-
tease and Phosphatase Inhibitor Cocktail (Thermo). 
Lysates were resolved by SDS-PAGE and transferred 
to Amersham Hybond ECL nitrocellulose membranes 
(GE Healthcare). All samples were denatured by heat-
ing at 100  °C for 10  min after mixing with 6× reduc-
ing sample buffer (60% glycerol, 300  mM Tris pH 6.8, 
12  mM EDTA, 12% SDS, 864  mM 2-mercaptoethanol, 
0.05% bromophenol blue). After blocking in 10% milk 
in PBST (PBS + 0.1% Tween-20), the following primary 
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antibodies (1:250) were applied in 5% milk in PBST: anti-
BMPR2 C-terminal domain (BD Biosciences, 612292), 
anti-phosphorylated SMAD1, 5, and 8 (Cell Signaling 
9516 and 13820), anti-SMAD1 (Cell Signaling 6944), 
and anti-β-actin (Sigma A2228). Appropriate HRP-
conjugated species-specific goat polyclonal second-
ary antibodies (1:1000; anti-mouse: Kirkegaard & Perry 
Laboratories, 04-18-06; and anti-rabbit: Cell Signaling, 
7074) were utilized and western blots were developed by 
chemiluminescence using WesternBright Quantum or 
Sirius substrate (Advansta). Stripping of membranes for 
re-probing was accomplished using Gentle Review Strip-
ping Buffer (VWR). Western blots were visualized using a 
LiCor C-Digit imager and quantified by ImageJ (ImageJ, 
RRID:SCR_003070).
Statistical analyses
Statistical analyses were performed using GraphPad 
Prism 5 as described in each respective figure legend or 
in the text. A p-value of < 0.05 was considered significant.
Results
Assay development
We first established a modified immunoprecipitation 
assay wherein recombinant BMP2 was pulled down 
by BMPR2-ECD conjugated to Protein G beads; the 
unbound BMP2, found in the supernatant, was subse-
quently quantified by ELISA. A pilot dose–response 
series (data not shown) using beads loaded with 0.5 µg to 
3.0  µg BMPR2-ECD while holding BMP2 concentration 
constant led us to further optimize the assay using 2 µg 
BMPR2-ECD; this led to a 73% reduction in BMP2 signal 
(mean ± SEM: 73.00 ± 7.077; p < 0.0001 by paired t-test, 
n = 11), thus confirming the ligand-binding activity of 
BMPR2-ECD in this assay.
Identification of a putative neutralizing antibody
We then sought to identify an antibody capable of neu-
tralizing the ligand-binding activity of the BMPR2-ECD. 
This led us to examine 3F6, which is a mouse monoclo-
nal antibody raised against the N-terminus of BMPR2, 
and found a dose-dependent inhibition of BMPR2-ECD 
ligand-binding (Fig.  1); in this experimental design, the 
inhibition appears to saturate at an approximate ratio of 
2 µg BMPR2-ECD: 25 µg 3F6. Given that the commercial 
Fig. 1 Antibody 3F6 reduces BMPR2-ECD ligand-binding activity in a 
modified immunoprecipitation assay. Neutralizing the ligand-binding 
activity of BMPR2-ECD using various amounts of 3F6. Results are 
quantified by ELISA and expressed as mean ± SEM relative to the 
ligand-binding activity of BMPR2-ECD in the absence of 3F6. n ≥ 3 per 
condition. Asterisk indicates p < 0.05 by paired t test
Fig. 2 Antibody 3F6 reduces activation of BMP pathway in 
HEK293T cells. a Expression of endogenous BMPR2 by HEK293T 
cells compared to β-actin loading control. Approximate molecular 
weights are indicated. b, c BMP2 induces phosphorylation of 
SMAD1, 5, and 8 (pSMAD1,5,8) in HEK293T cells and this response is 
blunted by pre-treatment with 3F6. Approximate molecular weights 
are indicated in b. Results are quantified in c and expressed as 
mean ± SEM ratio of phosphorylated SMAD1,5,8: total SMAD1 relative 
to BMP2 treatment alone. No effect on BMP2-responsiveness was 
observed with pre-treatment using control ascites (Ctrl Asc.). n = 3 
per condition. Asterisk indicates p < 0.05 by paired t test
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availability of this antibody is as an ascites preparation, 
specificity of this assay was confirmed by demonstrating 
that ligand-binding activity of BMPR2-ECD is unchanged 
in the presence of non-specific, negative control ascites 
(p = 0.9135 by paired t test, n = 3).
Validation of neutralizing activity in a cell‑based assay
We next established a cell-based assay to test the hypoth-
esis that 3F6 pretreatment attenuates the BMP-respon-
siveness of HEK293T cells, which express BMPR2 
endogenously (Fig.  2a) and mount a robust activation 
of SMAD1, 5, and 8 in response to exogenous BMP2 
(Fig. 2b). Pre-treatment with control ascites had no effect 
on the BMP2-induced pathway activation (Fig. 2b, c), but 
the 3F6 antibody did in fact blunt the cellular response to 
BMP2 (Fig. 2b, c).
To confirm the specificity of 3F6 against BMPR2, we 
used lentiviral transduction to generate HEK293T cells 
in which BMPR2 expression is stably knocked-down by 
shRNA; reduced BMPR2 transcript and BMPR2 protein 
levels were confirmed by quantitative RT-PCR (Fig.  3a) 
and immunoblot (Fig.  3b, c), respectively. 3F6 had no 
impact on the BMP2-responsiveness in this cell line 
(Fig. 3d, e).
Discussion
The BMP signaling pathway plays essential roles in nor-
mal metazoan development and tissue homeostasis 
[4]. Remarkably, the same basic pathway architecture is 
conserved throughout evolution: extracellular dimeric 
ligands interact with complexes of type 1 and type 2 
receptors on the cell surface to activate a class of intra-
cellular effectors and regulate cellular differentiation and/
or behavior via genomic and non-genomic means. Gene 
duplication events are thought to have given rise to the 
highly homologous, complex, and promiscuous BMP 
pathway present in mammals. This complexity creates 
Fig. 3 Antibody 3F6 has no effect on BMP-responsiveness in BMPR2 knock-down HEK293T cells. a Expression levels of endogenous BMPR2 in 
scramble control HEK293T cells (Control) and HEK293T cells carrying anti-BMPR2 shRNA (BMPR2-KD) compared to HPRT1 loading control. Data 
are expressed as normalized to scramble control (Control) using the  2−∆∆Ct method. n = 6 per condition. Asterisk indicates p < 0.05 by unpaired t 
test. b, c Expression of endogenous BMPR2 in scramble control HEK293T cells (Control) and BMPR2-KD HEK293T cells compared to β-actin loading 
control. Approximate molecular weights are indicated in b. Representative immunoblot is shown in b and results from three independent runs 
are quantified in c (data are expressed as mean ± SEM ratio of BMPR2: β-actin normalized to scramble control (Relative Expression)). Asterisk 
indicates p < 0.05 by paired t test. d, e BMP2 induces phosphorylation of SMAD1, 5, and 8 (pSMAD1,5,8) in BMPR2-KD HEK293T cells. No effect on 
BMP2-responsiveness of BMPR2-KD HEK293T cells was observed with pre-treatment using control ascites (Ctrl Asc.) or 3F6. Approximate molecular 
weights are indicated in d. Results are quantified in E and expressed as mean ± SEM ratio of phosphorylated SMAD1,5,8: total SMAD1 relative to 
BMP2 treatment alone (Relative pS1:S1). n = 4 per condition
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significant challenges for mechanistic studies examining 
the BMP pathway in model organisms and, moreover, 
devising strategies for modulating the activity of specific 
BMP pathway components to advance human health. 
This has led some investigators to develop monoclo-
nal antibodies that neutralize the activity of BMP path-
way components; notable examples include neutralizing 
antibodies against the extracellular antagonists Noggin 
and Gremlin and the integral transmembrane receptors 
ACVR2A, ACVR2B, and ACVR1 [8–13].
In this study, we sought to identify antibody(ies) capa-
ble of blocking the activity of BMPR2. We started our 
search with three strict criteria: (1) the antibody must be 
raised against the region of BMPR2 exposed to the extra-
cellular environment, i.e., the N-terminal ligand-binding 
domain; (2) the antibody must be monoclonal to pro-
mote specificity of action; and (3) the antibody must be 
purchasable from a commercial source so that it may be 
readily available to the field. 3F6 from Thermo Fisher Sci-
entific met these qualifications. No funding of any kind 
was sought from or received from this vendor. Using a 
cell-free immunoprecipitation assay quantified by ELISA, 
we determined that 3F6 is capable of blocking ligand-
binding by recombinant BMPR2-ECD. We then extended 
this work to examine neutralization of endogenous 
BMPR2 by 3F6 in HEK293T cells and obtained consistent 
results.
In the course of this study, we also performed pre-
liminary analyses on 9A10 and 1F12, both of which are 
mouse monoclonal antibodies raised against the N-ter-
minus of BMPR2 (produced by Abcam and Thermo 
Fisher Scientific, respectively). We were unable to achieve 
neutralizing ability by 9A10 in our cell-free assay and this 
antibody was eliminated from further analysis. In con-
trast, pilot data suggest that 1F12 is capable of blocking 
ligand-binding by recombinant BMPR2-ECD; we were 
unable to further validate this result in our cell-based 
assay due to challenges with consistent availability from 
the vendor.
Given that BMPR2 is widely expressed, our results 
provide proof-of-concept data for a novel strategy 
whereby investigators may inhibit BMPR2 function 
in various physiological contexts. When coupled with 
other inhibitors of the BMP pathway [6], 3F6 may pro-
vide novel insights into the mechanisms by which BMP 
signaling regulates embryogenesis and postnatal tissue 
homeostasis.
Limitations
The primary limitation of this study is the fact that the 
characterization and validation of 3F6 was performed 
in HEK293T cells as opposed to primary cells or in vivo. 
This approach was advantageous due to the ease of use, 
availability, ability to be stably transduced by lentivirus, 
and strong BMP-responsiveness of these cells. Addition-
ally, our study is limited by the examination of 3F6’s abil-
ity to block interaction of BMPR2 with a single ligand, 
namely BMP2. Structural studies indicate that all BMP 
ligands interact with the same region on the extracellu-
lar face of BMPR2 [14] and that the affinity of BMPR2 for 
BMP2 is relatively similar to that of other ligands [15]. 
That said, given these limitations, we encourage investi-
gators to examine the functional impact and specificity 
of 3F6 treatment on primary cells and/or tissues in their 
own context(s) of interest.
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